Clinical utility of the prognostic nutritional index in patients with metastatic hormone‐sensitive prostate cancer: A retrospective, multicenter, cohort study
- 10 September 2023
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 83 (16) , 1610-1618
Abstract
Background: The prognostic nutritional index (PNI) based on the serum albumin level and the lymphocyte count has been investigated as a prognostic factor in patients with malignant tumors. However, it has been poorly studied in prostate cancer (PCa), and little is known about its clinical utility.Methods: Clinical data of 353 patients with de novo, metastatic, hormone‐sensitive PCa (mHSPC) who received androgen deprivation therapy (ADT) were obtained from multiple institutions between 2000 and 2019. The impacts of the pretreatment PNI level on treatment response and survival, together with clinical parameters, were examined. The Mann−Whitney U test, Cox proportional hazards models, and Kaplan−Meier methods were used to evaluate significance.Results: The median age and initial prostate‐specific antigen level were 73 and 266.18 ng/mL, respectively. Patients with a low PNI had shorter progression‐free survival (PFS), cancer‐specific survival (CSS), and overall survival (OS) (p < 0.0001). On multivariate analysis, low PNI was an independent prognostic factor for OS (p = 0.0027, HR = 1.65), as well as advanced age (p = 0.049, HR = 1.38), the International Society of Urological Pathology (ISUP) grade group (GG) 5 (p = 0.0027, HR = 1.69), and elevated lactate dehydrogenase (LDH) (p < 0.0001, HR = 2.08). A propensity score‐matching analysis showed that the PNI level remained a significant prognostic biomarker for PFS (p = 0.0263), CSS (p = 0.0006), and OS (p = 0.0015). Furthermore, a novel risk classification using PNI, LDH, and the ISUP GG was established to stratify patients' prognosis. An increase in the number of risk factors was significantly correlated with poor outcomes.Conclusions: A low pretreatment PNI might be an effective biomarker of poor treatment response and survival in patients with mHSPC undergoing ADT.Keywords
Funding Information
- Japan Society for the Promotion of Science (23K15780)
This publication has 26 references indexed in Scilit:
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerNew England Journal of Medicine, 2019
- Apalutamide for Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2019
- Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate CancerEuropean Urology Oncology, 2019
- Long-term impact of prognostic nutritional index in cervical esophageal squamous cell carcinoma patients undergoing definitive radiotherapyAnnals of Translational Medicine, 2019
- The role of immunonutritional support in cancer treatment: Current evidenceClinical Nutrition, 2017
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2017
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinomaSurgery, 2013
- The Immunobiology of Cancer Immunosurveillance and ImmunoeditingImmunity, 2004
- IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature, 2001